TuisAGIO • BMV
add
Agios Pharmaceuticals Inc
Vorige sluiting
$983,02
Jaarwisseling
$397,93 - $983,02
Markkapitalisasie
3,18 mjd USD
P/V-verhouding
-
Dividend-opbrengs
-
Primêre beurs
NASDAQ
Marknuus
Finansieel
Inkomstestaat
Inkomste
Netto inkomste
| (USD) | Sep. 2024info | J/J-verandering |
|---|---|---|
Inkomste | 8,96 m | 21,15% |
Bedryfskoste | 38,54 m | 49,24% |
Netto inkomste | 947,92 m | 1 137,97% |
Netto winsgrens | 10,57 k | 956,76% |
Wins per aandeel | -1,47 | 10,66% |
EBITDA | -101,47 m | -2,21% |
Effektiewe belastingkoers | 5,31% | — |
Balansstaat
Totale bates
Totale aanspreeklikheid
| (USD) | Sep. 2024info | J/J-verandering |
|---|---|---|
Kontant en korttermynbeleggings | 1,00 mjd | 55,18% |
Totale bates | 1,79 mjd | 77,89% |
Totale aanspreeklikheid | 165,12 m | 37,13% |
Totale ekwiteit | 1,63 mjd | — |
Uitstaande aandele | 57,03 m | — |
Prys om te bespreek | 34,46 | — |
Opbrengs op bates | -20,04% | — |
Opbrengs op kapitaal | -21,31% | — |
Kontantvloei
Netto kontantverandering
| (USD) | Sep. 2024info | J/J-verandering |
|---|---|---|
Netto inkomste | 947,92 m | 1 137,97% |
Kontant van bedrywe | -84,22 m | -36,62% |
Kontant van beleggings | 250,79 m | 537,49% |
Kontant van finansiering | 2,64 m | 40,12% |
Netto kontantverandering | 169,21 m | 928,66% |
Beskikbare kontantvloei | -3,03 m | 95,64% |
Meer oor
Agios Pharmaceuticals Inc. is a publicly trading American pharmaceutical company pioneering therapies for genetically defined diseases, with a near-term focus on developing therapies for hemolytic anemias. The company was founded in 2008 by Lewis Cantley, Tak Mak and Craig Thompson. Agios is a Delaware corporation headquartered in Cambridge, Massachusetts. The company tendered an initial public offering in July 2013. Wikipedia
Gestig
2008
Webwerf
Werknemers
385
